Latest News

First chemoimmunotherapy regimen approved by FDA for patients with diffuse large B-cell lymphoma

Today, the U.S. Food and Drug Administration granted accelerated approval to Polivy (polatuzumab vedotin-piiq), in combination with the chemotherapy bendamustine and a rituximab product (a combination known as “BR”), to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies.

Source link

Related posts

Study sheds light on rhodopsin dynamics in the retina


STAT Plus: Pharmalittle: Opioid companies failed to halt suspicious orders; U.K. diabetics are rationing insulin


Medical News Today: What to know about nut allergies


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy